MIRA INFORM REPORT

 

 

Report No. :

500661

Report Date :

29.03.2018

 

 

IDENTIFICATION DETAILS

 

Name :

SANDOZ PRIVATE LIMITED (w.e.f 23.04.2003)

 

 

Formerly Known As :

SANDOZ PHARMA (INDIA) PRIVATE LIMITED

 

 

Registered Office :

Sandoz House, Dr. Annie Besant Road, Worli, Mumbai-400018, Maharashtra

Tel. No.:

91-22-27639000/27639090/61527900/27639468

 

 

Country :

India

 

 

Financials (as on) :

31.03.2017

 

 

Date of Incorporation :

30.03.1995

 

 

Com. Reg. No.:

11-086989

 

 

Capital Investment / Paid-up Capital :

INR 32.000 Million

 

 

CIN No.:

[Company Identification No.]

U24230MH1995PTC086989

 

 

IEC No.:

0396036287

 

 

GSTN :

[Goods & Service Tax Registration No.]

Not Divulged

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

Not Available

 

 

PAN No.:

[Permanent Account No.]

AAACS9267J

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Subject is engaged in the manufacturing and trading of pharmaceutical products  (Registered Activity)

 

 

No. of Employees :

Information denied by the management

 

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

 

MIRA’s Rating :

A+

 

Credit Rating

Explanation

Rating Comments

A+

Low Risk

Business dealings permissible with low risk of default

 

Maximum Credit Limit :

USD 14000000

 

 

Status :

Excellent

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Exists  

 

 

Comments :

Subject was incorporated in the year 1995. It is a subsidiary of Novartis Holding AG, Basel, Switzerland.

 

The company is a manufacturer and trader of pharmaceutical products.

 

As per the financial records of 2017, the company has achieved an average net profit margin of 4.14% but has reported a decline in its revenue as compared to the previous year.

 

The company possesses sound financial position marked by above average networth base along with negligible debt level and favourable liquidity position.

 

Rating takes into consideration the company’s satisfactory Earnings Per Share (EPS) of INR 157.94 as against its Face Value (FV) of INR 10.

 

Rating takes into consideration the strength that the company derives from its holding company and its experienced management team.

 

Business is active. Payments are reported to be regular and as per commitment.

 

In view of aforesaid, the company can be considered for business dealings at usual trade terms and condition.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List

 

Country Name

Previous Rating

(30.09.2017)

Current Rating

(31.12.2017)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderately Low Risk

 

B1

Moderate Risk

 

B2

Moderately High Risk

 

C1

High Risk

 

C2

Very High Risk

 

D

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

Not Available

Rating

Not Available

Rating Explanation

Not Available

Date

Not Available

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2016.

 

BIFR (Board for Industrial & Financial Reconstruction) LISTING STATUS

 

Subject’s name is not listed as a Sick Unit in the publicly available BIFR (Board for Industrial & Financial Reconstruction) list as of 29.03.2018

 

IBBI (Insolvency and Bankruptcy Board of India) LISTING STATUS

 

Subject’s name is not listed in the publicly available IBBI (Insolvency and Bankruptcy Board of India) list as of report date.

 

INFORMATION DENIED BY

 

Name :

Mr. Nishith Laxmikant Vaidya

Designation :

Director

Contact No.:

91-22-27639000 / 100

Date :

29.03.2018

 

LOCATIONS

 

Registered Office :

Sandoz House, Dr. Annie Besant Road, Worli, Mumbai-400018, Maharashtra, India 

Tel. No.:

91-22-27639000/27639090/27639468

Fax No.:

91-22-24981620/ 24982099 / 27639064 / 27639012

E-Mail :

rohit.bagadia@sandoz.com

Website :

http://www.sandoz.com

 

 

Factory 1:

MIDC, Plot No. 8-A/2, 8-B TTC Industrial Area, Kawle Block, Village Dighe, Opposite Thane Belapur Road, Navi Mumbai – 400 708, Maharashtra, India

Tel No.:

91-22-24982091/ 27639275/27639000

Fax No. :

91-22-24982099/27639064

 

 

Factory 2:

Plot No. 1 L-1, Additional MIDC, MIDC Industrial Area Mahad, District Raigad 402 301, Maharashtra India

Tel No.:

91-2145-235000

Fax No. :

91-2145-251066

 

 

Factory 3:

Ithink Techno Campus, Phase 1, Alpha Building, Ground Floor, Off. Jogeshwari Vikroli Link Road Kanjurmarg (East), Mumbai-400042, Maharashtra, India

Tel No.:

91-22-61529700

Fax No. :

91-22-61529777

 

 

DIRECTORS

 

As on 31.03.2017

 

Name :

Mr. Andreas Brutsche Michael

Designation :

Director 

Address :

Im Schindwasen 5, Britzingen 79379 Mullheim

Date of Birth/Age :

17.09.1962

Date of Appointment :

29.08.2013

DIN No.:

06659893

 

 

Name :

Mrs. Rashmi Ranjan Patra

Designation :

Director

Address :

Flat No 1701, B Wing, Eldora Co-Operative Housing Society, Hiranandani Gardens, Hiranandani Powai, Mumbai-400076, Maharashtra, India

Date of Birth/Age :

02.04.1962

Date of Appointment :

11.03.2017

PAN No.:

AEHPP3687F

DIN No.:

06472839

 

 

Name :

Mr. Nishith Laxmikant Vaidya

Designation :

Director

Address :

A/904, Picadilly, Shiv Sai Paradise Complex, Majiwada Road, Behind Fatima Church, Thane- 400601, Maharashtra, India

Date of Birth/Age :

06.07.1963

Date of Appointment :

27.10.2016

DIN No.:

07605129

 

 

MAJOR SHAREHOLDERS

 

As on 31.03.2017

 

Names of Shareholders

No. of Shares

Novartis Holding AG, Switzerland

3199995

Novartis  AG, Switzerland

5

Total

3200000

 

Equity Share Break up (Percentage of Total Equity)

 

As on 23.09.2016

 

Category

Percentage

Promoters (Others – Foreign Body Corporate)

100.00

Total 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Subject is engaged in the manufacturing and trading of pharmaceutical products  (Registered Activity)

 

 

Products / Services :

Item Code No.

Products/Services Description

30049099

Tacrolimus

30049079

Valsartan

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Divulged 

 

 

Imports :

Not Divulged 

 

 

Terms :

Not Divulged 

 

PRODUCTION STATUS – (NOT AVAILABLE)

 

GENERAL INFORMATION

 

Suppliers :

 

Reference :

Not Divulged

Name of the Person :

--

Contact No.:

--

Since How Long Known :

--

Maximum Limit Dealt :

--

Experience :

--

Remark:

--

 

 

Customers :

 

Reference :

Not Divulged

Name of the Person :

--

Contact No.:

--

Since How Long Known :

--

Maximum Limit Dealt :

--

Experience :

--

Remark:

--

 

 

No. of Employees :

Information denied by the management

 

 

Bankers :

Banker Name :

Not Divulged

Branch :

--

Person Name (With Designation) :

--

Contact Number :

--

Name of Account Holder :

--

Account Number :

--

Account Since (Date/Year of Account Opening) :

--

Average Balance Maintained :

--

Credit Facilities Enjoyed (CC/OD/Term Loan) :

--

Account Operation :

--

Remark :

--

 

 

Facilities :

Secured Loan

31.03.2017

(INR in Million)

31.03.2016

(INR in Million)

Short-term borrowings

 

 

Working capital loans from banks (Secured by Lien/Hypothecation of all inventories and book debts)

0.100

372.000

 

 

 

Total

0.100

372.000

 

Auditors :

 

Name :

Lovelock and Lewes

Chartered Accountants

Address :

252, Veer Savarkar Marg, Shivaji Park, Dadar, Mumbai-400028, Maharashtra, India

Income-tax PAN of auditor or auditor's firm :

AABFL5878L

 

 

Memberships :

Not Available

 

 

Collaborators :

Not Available

 

 

Holding Company:

  • Novartis Holding AG, Basel, Switzerland

 

 

Ultimate Holding Company:

  • Novartis AG, Basel, Switzerland

 

 

Fellow Subsidiaries:

  • Chiron Behring Vaccines Private Limited, India
  • EBEWE Pharma GesmbH Nfg. KG, Austria
  • Hexal AG, Germany
  • Lek Pharmaceuticals D.D., Slovenia
  • Lek S.A., Poland
  • Novartis (Bangladesh) Limited, Bangladesh
  • Novartis Asia Pacific Pharmaceuticals Pte. Limited,
  • Singapore
  • Novartis Biociencias S.A., Brazil
  • Novartis Consumer Health S.A., Switzerland
  • Novartis France S A, France
  • Novartis Healthcare Private Limited, India
  • Novartis India Limited, India
  • Novartis International AG, Switzerland
  • Novartis Pharma (Pakistan) Limited, Pakistan
  • Novartis Pharma AG, Switzerland
  • Novartis Thailand Limited, Thailand
  • Novartis UK Limited, United Kingdom
  • Salutas Pharma GmbH, Germany
  • Sandoz S.A (Pty) Limited, South Africa
  • Sandoz AG, Switzerland
  • Sandoz Brazil, Brazil
  • Sandoz Canada Inc., Canada
  • Sandoz GmbH, Austria
  • Sandoz Iiac Sanayi Ve Ticaret A.S., Turkey
  • Sandoz International GmbH, Germany
  • Sandoz K.K., Japan
  • Sandoz Philippines Corporation, Philippines
  • Sandoz Syntek Ilac Hammaddeleri San. Ve Tic. As,
  • Turkey
  • Sandoz US, United States of America
  • Sc Sandoz S.R.L., Romania

 


CAPITAL STRUCTURE

 

As on 31.03.2017

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

5000000

Equity Shares

INR 10/- each

INR 50.000 Million

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

3200000

Equity Shares

INR 10/- each

INR 32.000 Million

 

 

 

 

 


 

FINANCIAL DATA

[all figures are INR Million]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2017

31.03.2016

31.03.2015

I.      EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

32.000

32.000

32.000

(b) Reserves and Surplus

4857.600

4352.200

3723.000

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

4889.600

4384.200

3755.000

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

0.000

(b) Deferred tax liabilities (Net)

186.900

123.400

161.400

(c) Other long-term liabilities

17.100

18.200

19.000

(d) long-term provisions

366.300

332.100

232.800

Total Non-current Liabilities (3)

570.300

473.700

413.200

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short-term borrowings

3319.600

3758.100

5957.100

(b) Trade payables

2559.300

2905.800

3598.800

(c) Other current liabilities

170.700

181.500

121.400

(d) Short-term provisions

157.300

112.200

95.200

Total Current Liabilities (4)

6206.900

6957.600

9772.500

 

 

 

 

TOTAL

11666.800

11815.500

13940.700

 

 

 

 

II.    ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

3361.800

3252.500

4258.000

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Tangible assets capital work-in-progress

368.500

436.000

320.500

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d) Long-term loans and advances

891.000

771.100

610.800

(e) Other Non-current assets

4.800

4.800

2.500

Total Non-Current Assets

4626.100

4464.400

5191.800

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

3857.000

4181.600

5657.700

(c) Trade receivables

1106.600

1348.100

2164.600

(d) Cash and bank balances

12.300

18.800

11.700

(e) Short-term loans and advances

1273.800

1015.000

910.700

(f) Other current assets

791.000

787.600

4.200

Total Current Assets

7040.700

7351.100

8748.900

 

 

 

 

TOTAL

11666.800

11815.500

13940.700

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2017

31.03.2016

31.03.2015

 

SALES

 

 

 

 

Revenue from operations

12218.600

14695.100

14037.700

 

Other Income

245.700

29.500

30.700

 

TOTAL

12464.300

14724.600

14068.400

 

 

 

 

 

Less

EXPENSES

 

 

 

 

Cost of Materials Consumed

5633.400

7045.900

7000.400

 

Purchases of Stock-in-Trade

989.100

480.200

764.600

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

57.200

570.800

13.100

 

Employee benefit expense

1762.500

1625.200

1407.800

 

CSR expenditure

16.600

14.600

12.700

 

Other expenses

2361.300

3072.800

2984.400

 

TOTAL

10820.100

12809.500

12183.000

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

1644.200

1915.100

1885.400

 

 

 

 

 

Less

FINANCIAL EXPENSES

308.900

454.600

568.900

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

1335.300

1460.500

1316.500

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION

478.300

542.200

555.900

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

857.000

918.300

760.600

 

 

 

 

 

Less

TAX

351.600

289.100

254.400

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX

505.400

629.200

506.200

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE

BROUGHT FORWARD

4352.200

3723.000

3216.800

 

 

 

 

 

 

Balance Carried to the B/S

4857.600

4352.200

3723.000

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

F.O.B. Value of Exports

9969.800

12583.300

11832.300

 

TOTAL EARNINGS

9969.800

12583.300

11832.300

 

 

 

 

 

 

IMPORTS

 

 

 

 

Raw Materials

3851.500

3544.100

4398.500

 

Components and spare parts

31.300

21.800

20.300

 

Capital Goods

226.400

182.100

321.600

 

TOTAL IMPORTS

4109.200

3748.000

4740.400

 

 

 

 

 

 

Earnings / (Loss) Per Share (INR)

157.94

196.63

158.18

 

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

Particulars

 

31.03.2017

31.03.2016

31.03.2015

Current Maturities of Long term debt

NA

NA

NA

Net cash flows from (used in) operations

1349.000

3080.900

663.100

Net cash flows from (used in) operating activities

1191.100

3110.100

874.200

 

KEY RATIOS

 

EFFICIENCY RATIOS

 

PARTICULARS

 

31.03.2017

31.03.2016

31.03.2015

Average Collection Days

(Sundry Debtors / Income * 365 Days)

33.06

33.48

56.28

 

 

 

 

Account Receivables Turnover

(Income / Sundry Debtors)

11.04

10.90

6.49

 

 

 

 

Average Payment Days

(Sundry Creditors / Purchases * 365 Days)

141.06

140.93

169.16

 

 

 

 

Inventory Turnover

(Operating Income / Inventories)

0.43

0.46

0.33

 

 

 

 

Asset Turnover

(Operating Income / Net Fixed Assets)

0.44

0.52

0.41

 

LEVERAGE RATIOS

 

PARTICULARS

 

31.03.2017

31.03.2016

31.03.2015

Debt Ratio

((Borrowing + Current Liabilities) / Total Assets)

0.53

0.59

0.70

 

 

 

 

Debt Equity Ratio

(Total Liability / Networth)

0.68

0.86

1.59

 

 

 

 

Current Liabilities to Networth

(Current Liabilities / Net Worth)

1.27

1.59

2.60

 

 

 

 

Fixed Assets to Networth

(Net Fixed Assets / Networth)

0.76

0.84

1.22

 

 

 

 

Interest Coverage Ratio

(PBIT / Financial Charges)

5.32

4.21

3.31

 

PROFITABILITY RATIOS

 

PARTICULARS

 

 

31.03.2017

31.03.2016

31.03.2015

Net Profit Margin

((PAT / Sales) * 100)

%

4.14

4.28

3.61

 

 

 

 

 

Return on Total Assets

((PAT / Total Assets) * 100)

%

4.33

5.33

3.63

 

 

 

 

 

Return on Investment (ROI)

((PAT / Networth) * 100)

%

10.34

14.35

13.48

 

SOLVENCY RATIOS

 

PARTICULARS

 

31.03.2017

31.03.2016

31.03.2015

Current Ratio

(Current Assets / Current Liabilities)

1.13

1.06

0.90

 

 

 

 

Quick Ratio

((Current Assets – Inventories) / Current Liabilities)

0.51

0.46

0.32

 

 

 

 

G-Score Ratio Financial

(Networth / Total Assets)

0.42

0.37

0.27

 

 

 

 

G-Score Ratio Debt

(Debts / Equity Capital)

103.74

117.44

186.16

 

 

 

 

G-Score Ratio Liquidity

(Total Current Assets / Total Current Liabilities)

1.13

1.06

0.90

 

Total Liability = Short-term Debt + Long-term Debt + Current Maturities of Long-term debts

 

 

LEGAL CASES

 

ATTACHED 

 

FINANCIAL ANALYSIS

[all figures are in INR Million]

 

DEBT EQUITY RATIO

 

Particular

31.03.2015

31.03.2016

31.03.2017

 

(INR In Million)

(INR In Million)

(INR In Million)

Share Capital

32.000

32.000

32.000

Reserves & Surplus

3723.000

4352.200

4857.600

Money received against share warrants

0.000

0.000

0.000

Share Application money pending allotment

0.000

0.000

0.000

Net worth

3755.000

4384.200

4889.600

 

 

 

 

Long-term borrowings

0.000

0.000

0.000

Short term borrowings

5957.100

3758.100

3319.600

Total borrowings

5957.100

3758.100

3319.600

Debt/Equity ratio

1.586

0.857

0.679

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2015

31.03.2016

31.03.2017

 

(INR In Million)

(INR In Million)

(INR In Million)

Sales

14037.700

14695.100

12218.600

 

 

4.683

(16.853)

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2015

31.03.2016

31.03.2017

 

INR In Million

INR In Million

INR In Million

Sales

14037.700

14695.100

12218.600

Profit/ (Loss)

506.200

629.200

505.400

 

3.61%

4.28%

4.14%

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of establishment

Yes

2]

Constitution of the entity Incorporation details

Yes

3]

Locality of the entity

Yes

4]

Premises details

No

5]

Buyer visit details

--

6]

Contact numbers

Yes

7]

Name of the person contacted

No

8]

Designation of contact person

No

9]

Promoter’s background

Yes

10]

Date of Birth of Proprietor / Partners / Directors

Yes

11]

Pan Card No. of Proprietor / Partners

Yes

12]

Voter Id Card No. of Proprietor / Partners

No

13]

Type of business

Yes

14]

Line of Business

Yes

15]

Export/import details (if applicable)

No

16]

No. of employees

No

17]

Details of sister concerns

Yes

18]

Major suppliers

No

19]

Major customers

No

20]

Banking Details

No

21]

Banking facility details

Yes

22]

Conduct of the banking account

--

23]

Financials, if provided

Yes

24]

Capital in the business

Yes

25]

Last accounts filed at ROC, if applicable

Yes

26]

Turnover of firm for last three years

Yes

27]

Reasons for variation <> 20%

--

28]

Estimation for coming financial year

No

29]

Profitability for last three years

Yes

30]

Major shareholders, if available

Yes

31]

External Agency Rating, if available

No

32]

Litigations that the firm/promoter involved in

Yes

33]

Market information

--

34]

Payments terms

No

35]

Negative Reporting by Auditors in the Annual Report

No

 

BACKGROUND

The company was incorporated on 30th March, 1995 as Sandoz Pharma (India) Private Limited. The name of the company was changed to Sandoz Private Limited on 23rd April, 2003. The company is engaged in the manufacturing and trading of pharmaceutical products.

 

UNSECURED LOAN

PARTICULAR

31.03.2017

(INR in Million)

31.03.2016

(INR in Million)

Short-term borrowings

 

 

Working capital loans from banks

1549.500

2146.100

Intercorporate deposits

1770.000

1240.000

Total

3319.500

3386.100

 

INDEX OF CHARGES

 

SNo

SRN

Charge Id

Charge Holder Name

Date of Creation

Date of Modification

Date of Satisfaction

Amount

Address

1

Y10257966

90158196

Standard Chartered Bank

27/06/2003

28/03/2007

-

1080000000.0

90, M G ROAD, FORT, MUMBAI-400001, MAHARASHTRA, INDIA

2

B91215632

90157117

UNION BANK OF INDIA

19/03/1999

19/03/1999

05/12/2013

100000000.0

INDU. FINANCE BRANCH; UNION BANK BHAVAN1ST FLOOR; 239; VIDHAN BHAVAN MARG; NARIMAN POINT MUMBAI-400021, MAHARASHTRA, INDIA

3

B84014166

90157354

BANQUE NATIONAL DE PARIS

06/12/1999

-

06/09/2013

50000000.0

FRENCH BANK BULD.; 62 HOMJI STREET; FORT MUMBAI-400001, MAHARASHTRA, INDIA

4

B82172941

90156560

STANDARD CHARTERED BANK

10/04/1997

18/08/1999

14/08/2013

100000000.0

M. G. ROAD FORT MUMBAI-400001, MAHARASHTRA, INDIA

 

FIXED ASSETS

  • Land
  • Building
  • Furniture and Fixture
  • Computer
  • Plant and equipment
  • Vehicles
  • Office equipment

 

 

 

 

 




CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

FOREIGN EXCHANGE RATES

 

Currency

 

Unit

INR

US Dollar

1

INR 65.06

UK Pound

1

INR 92.06

Euro

1

INR 80.37

 

 

INFORMATION DETAILS

 

Information Gathered by :

ARC  

 

 

Analysis Done by :

NYT

 

 

Report Prepared by :

RKI

 


 

SCORE FACTORS

 

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

YES

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

 

RATING EXPLANATIONS

 

Credit Rating

Explanation

Rating Comments

A++

Minimum Risk

Business dealings permissible with minimum risk of default

A+

Low Risk

Business dealings permissible with low risk of default

A

Acceptable Risk

Business dealings permissible with moderate risk of default

B

Medium Risk

Business dealings permissible on a regular monitoring basis

C

Medium High Risk

Business dealings permissible preferably on secured basis

D

High Risk

Business dealing not recommended or on secured terms only

NB

New Business

No recommendation can be done due to business in infancy stage

NT

No Trace

No recommendation can be done as the business is not traceable

 

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

 

·         Financial condition covering various ratios

·         Company background and operations size

·         Promoters / Management background

·         Payment record

·         Litigation against the subject

·         Industry scenario / competitor analysis

·         Supplier / Customer / Banker review (wherever available)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.